OA09124A - Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis. - Google Patents

Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.

Info

Publication number: OA09124A
Authority: OA; OAPI
Prior art keywords: preparation; immunomodulatory; medicaments; intended; acquired immunodeficiency
Prior art date: 1987-01-21

Application number

OA59616A

Other languages

English (en)

French (fr)

Inventor

Shelly Marc Yves Franc Clement

Original Assignee

Shelly Marc Yves Franck Clemen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-21

Filing date

1989-07-20

Publication date

1991-10-31

1989-07-20 Application filed by Shelly Marc Yves Franck Clemen filed Critical Shelly Marc Yves Franck Clemen

1991-10-31 Publication of OA09124A publication Critical patent/OA09124A/xx

Links

BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title abstract 4
208000029483 Acquired immunodeficiency Diseases 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title abstract 2
229960005181 morphine Drugs 0.000 title abstract 2
230000000840 anti-viral effect Effects 0.000 title 1
239000003814 drug Substances 0.000 title 1
230000002519 immonomodulatory effect Effects 0.000 title 1
239000003443 antiviral agent Substances 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
229940121354 immunomodulator Drugs 0.000 abstract 1
230000002584 immunomodulator Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
229960003086 naltrexone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA59616A 1987-01-21 1989-07-20 Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis. OA09124A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8700670A FR2609632B1 (fr)	1987-01-21	1987-01-21	Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage

Publications (1)

Publication Number	Publication Date
OA09124A true OA09124A (fr)	1991-10-31

Family

ID=9347124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA59616A OA09124A (fr)	1987-01-21	1989-07-20	Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.

Country Status (9)

Country	Link
EP (1)	EP0278821B1 (de)
JP (1)	JPH02502278A (de)
AT (1)	ATE112488T1 (de)
AU (1)	AU610561B2 (de)
DE (1)	DE3851711D1 (de)
DK (1)	DK524788A (de)
FR (1)	FR2609632B1 (de)
OA (1)	OA09124A (de)
WO (1)	WO1988005297A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5095035A (en) *	1981-07-31	1992-03-10	Eby Iii George A	Flavor stable zinc acetate compositions for oral absorption
US4877791A (en) *	1988-11-01	1989-10-31	Baker Cummins Pharmaceuticals, Inc.	Method of treatment for interestitial cystitis
US4857533A (en) *	1988-12-15	1989-08-15	Baker Cummins Pharmaceuticals, Inc.	Method of treatment for autoimmune diseases
US4863928A (en) *	1989-01-04	1989-09-05	Baker Cummins Pharmaceuticals, Inc.	Method of treatment for arthritic and inflammatory diseases
RU2058553C1 (ru) *	1994-03-18	1996-04-20	Иван Николаевич Головистиков	Способ определения супрессорного звена иммунного статуса человека
RU2056852C1 (ru) *	1994-03-18	1996-03-27	Иван Николаевич Головистиков	Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
US6274591B1 (en)	1997-11-03	2001-08-14	Joseph F. Foss	Use of methylnaltrexone and related compounds
ATE510534T1 (de) *	2002-03-14	2011-06-15	Euro Celtique Sa	Naltrexonhydrochlorid-zusammensetzungen
RU2224518C1 (ru) *	2003-02-10	2004-02-27	Дулькис Мария Дмитриевна	Жидкая лекарственная форма налтрексона
HRP20150037T4 (hr)	2003-04-08	2022-09-02	Progenics Pharmaceuticals, Inc.	Farmaceutske formulacije koje sadrže metilnaltrekson
RU2238093C1 (ru) *	2003-08-07	2004-10-20	Государственный научный центр вирусологии и биотехнологии "Вектор"	Фторированные производные 2-ароил-3-метил-6,7-дифторбенз[4,5]-имидазо[1,2-b][1,3]-тиазолов-ингибитор ы репродукции вируса кори
CN101171010B (zh)	2005-03-07	2014-09-17	芝加哥大学	阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en)	2005-03-07	2013-08-27	The University Of Chicago	Use of opioid antagonists
US8524731B2 (en)	2005-03-07	2013-09-03	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en)	2005-03-07	2017-05-30	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es)	2005-05-25	2007-11-28	Progenics Pharm Inc	Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es)	2005-05-25	2007-11-14	Progenics Pharm Inc	SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
CA2682129A1 (en)	2007-03-29	2008-10-09	Progenics Pharmaceuticals, Inc.	Crystal forms and uses thereof
US8546418B2 (en)	2007-03-29	2013-10-01	Progenics Pharmaceuticals, Inc.	Peripheral opioid receptor antagonists and uses thereof
PT2139890E (pt)	2007-03-29	2014-09-03	Wyeth Llc	Antagonistas do receptor opióide periférico e respectivas utilizações
EP2240489A1 (de)	2008-02-06	2010-10-20	Progenics Pharmaceuticals, Inc.	HERSTELLUNG UND VERWENDUNG VON (R), (R)-2,2ýBIS-METHYLNALTREXON
EP2278966B1 (de)	2008-03-21	2019-10-09	The University of Chicago	Behandlung mit opioid-antagonisten und mtor-inhibitoren
CA2676881C (en)	2008-09-30	2017-04-25	Wyeth	Peripheral opioid receptor antagonists and uses thereof
EP3416619A2 (de) *	2016-02-18	2018-12-26	Immune Therapeutics, Inc.	Verfahren zur auslösung einer anhaltenden immunreaktion
US11285192B2 (en)	2019-03-13	2022-03-29	Adamis Pharmaceuticals Corporation	Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
AU2020237248A1 (en) *	2019-03-13	2021-10-28	Adamis Pharmaceuticals Corporation	Formulation including a combination of beta-endorphin and adrenocorticotropic hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3332950A (en) *	1963-03-23	1967-07-25	Endo Lab	14-hydroxydihydronormorphinone derivatives

1987
- 1987-01-21 FR FR8700670A patent/FR2609632B1/fr not_active Expired - Lifetime
1988
- 1988-01-21 AT AT88400132T patent/ATE112488T1/de not_active IP Right Cessation
- 1988-01-21 JP JP87506276A patent/JPH02502278A/ja active Pending
- 1988-01-21 EP EP88400132A patent/EP0278821B1/de not_active Expired - Lifetime
- 1988-01-21 WO PCT/FR1988/000032 patent/WO1988005297A1/fr not_active Ceased
- 1988-01-21 AU AU11896/88A patent/AU610561B2/en not_active Ceased
- 1988-01-21 DE DE3851711T patent/DE3851711D1/de not_active Expired - Lifetime
- 1988-09-21 DK DK524788A patent/DK524788A/da not_active Application Discontinuation
1989
- 1989-07-20 OA OA59616A patent/OA09124A/xx unknown

Also Published As

Publication number	Publication date
AU1189688A (en)	1988-08-10
FR2609632A1 (fr)	1988-07-22
JPH02502278A (ja)	1990-07-26
EP0278821B1 (de)	1994-10-05
WO1988005297A1 (fr)	1988-07-28
DK524788D0 (da)	1988-09-21
EP0278821A1 (de)	1988-08-17
AU610561B2 (en)	1991-05-23
DK524788A (da)	1988-11-18
DE3851711D1 (de)	1994-11-10
FR2609632B1 (fr)	1991-03-29
ATE112488T1 (de)	1994-10-15

Publication	Publication Date	Title
AU1189688A (en)	1988-08-10	Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states
DK602988A (da)	1989-05-04	Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
FI862011A0 (fi)	1986-05-14	Terapeutiska nukleosider.
MX9203543A (es)	1992-07-01	Medicamento.
DE3776946D1 (de)	1992-04-09	Nasale verabreichung von arzneimitteln.
NO871549D0 (no)	1987-04-13	Medikament for behandling av oeyenbetennelser.
ES2130114T3 (es)	1999-07-01	5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
DE69129800D1 (de)	1998-08-20	Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
NL194728B (nl)	2002-09-02	Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
ATE190064T1 (de)	2000-03-15	Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
NL960024I2 (nl)	1997-06-02	Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
NO922936D0 (no)	1992-07-23	Fremstilling av fettsyremedikamenter
DE3887014D1 (de)	1994-02-24	Nukleoside, ihre Herstellung und pharmazeutische Zusammenstellungen.
DE68916387D1 (de)	1994-07-28	Verwendung von Nalmefen oder Naltrexon bei der Behandlung von Autoimmunerkrankungen.
DE3873327D1 (de)	1992-09-03	Arzneimittelzubereitung zur behandlung des immunmangels.
DK538888D0 (da)	1988-09-28	Anvendelse af castanosperminestere til fremstilling af et farmaceutisk praeparat
ATE82294T1 (de)	1992-11-15	Therapeutische nukleoside.
ES2108680T3 (es)	1998-01-01	Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
FR2361109A1 (fr)	1978-03-10	Medicaments anthelminthiques
WO1990005523A3 (en)	1990-07-12	Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
IT1225262B (it)	1990-11-05	Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
ES2066897T3 (es)	1995-03-16	5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
ATE84418T1 (de)	1993-01-15	2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
HUT54300A (en)	1991-02-28	Process for producing medicaments suitable for antiviral treatment